Literature DB >> 15221790

Harmonized microarray/mutation scanning analysis of TP53 mutations in undissected colorectal tumors.

Reyna Favis1, Jianmin Huang, Norman P Gerry, Alfred Culliford, Philip Paty, Thierry Soussi, Francis Barany.   

Abstract

Both the mutational status and the specific mutation of TP53 (p53) have been shown to impact both tumor prognosis and response to therapies. Molecular profiling of solid tumors is confounded by infiltrating wild-type cells, since normal DNA can interfere with detection of mutant sequences. Our objective was to identify TP53 mutations in 138 stage I-IV colorectal adenocarcinomas and liver metastases without first enriching for tumor cells by microdissection. To achieve this, we developed a harmonized protocol involving multiplex polymerase chain reaction/ligase detection reaction (PCR/LDR) with Universal DNA microarray analysis and endonuclease V/ligase mutation scanning. Sequences were verified using dideoxy sequencing. The harmonized protocol detected all 66 mutations. Dideoxy sequencing detected 41 out of 66 mutations (62%) using automated reading, and 59 out of 66 mutations (89%) with manual reading. Data analysis comparing colon cancer entries in the TP53 database (http://p53.curie.fr) with the results reported in this study showed that distribution of mutations and the mutational events were comparable. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15221790     DOI: 10.1002/humu.20069

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  8 in total

1.  Human endonuclease V as a repair enzyme for DNA deamination.

Authors:  Rongjuan Mi; Maria Alford-Zappala; Yoke W Kow; Richard P Cunningham; Weiguo Cao
Journal:  Mutat Res       Date:  2012-06-01       Impact factor: 2.433

2.  Multiplexed identification of blood-borne bacterial pathogens by use of a novel 16S rRNA gene PCR-ligase detection reaction-capillary electrophoresis assay.

Authors:  Maneesh R Pingle; Kathleen Granger; Philip Feinberg; Rebecca Shatsky; Bram Sterling; Mark Rundell; Eric Spitzer; Davise Larone; Linnie Golightly; Francis Barany
Journal:  J Clin Microbiol       Date:  2007-04-11       Impact factor: 5.948

3.  Multiplexed profiling of candidate genes for CpG island methylation status using a flexible PCR/LDR/Universal Array assay.

Authors:  Yu-Wei Cheng; Carrie Shawber; Dan Notterman; Philip Paty; Francis Barany
Journal:  Genome Res       Date:  2005-12-20       Impact factor: 9.043

4.  PCR/LDR/universal array platforms for the diagnosis of infectious disease.

Authors:  Maneesh Pingle; Mark Rundell; Sanchita Das; Linnie M Golightly; Francis Barany
Journal:  Methods Mol Biol       Date:  2010

5.  High sensitivity EndoV mutation scanning through real-time ligase proofreading.

Authors:  Hanna Pincas; Maneesh R Pingle; Jianmin Huang; Kaiqin Lao; Philip B Paty; Alan M Friedman; Francis Barany
Journal:  Nucleic Acids Res       Date:  2004-10-28       Impact factor: 16.971

6.  Development of multiplex PCR-ligase detection reaction assay for detection of West Nile virus.

Authors:  S Rondini; M R Pingle; S Das; R Tesh; M S Rundell; J Hom; S Stramer; K Turner; S N Rossmann; R Lanciotti; E G Spier; J Muñoz-Jordán; D Larone; E Spitzer; F Barany; L M Golightly
Journal:  J Clin Microbiol       Date:  2008-05-21       Impact factor: 5.948

7.  The signatures of autozygosity among patients with colorectal cancer.

Authors:  Manny D Bacolod; Gunter S Schemmann; Shuang Wang; Richard Shattock; Sarah F Giardina; Zhaoshi Zeng; Jinru Shia; Robert F Stengel; Norman Gerry; Josephine Hoh; Tomas Kirchhoff; Bert Gold; Michael F Christman; Kenneth Offit; William L Gerald; Daniel A Notterman; Jurg Ott; Philip B Paty; Francis Barany
Journal:  Cancer Res       Date:  2008-03-28       Impact factor: 12.701

8.  Microsphere-based rolling circle amplification microarray for the detection of DNA and proteins in a single assay.

Authors:  Tania Konry; Ryan B Hayman; David R Walt
Journal:  Anal Chem       Date:  2009-07-15       Impact factor: 6.986

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.